Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571687 | 1.00 | MTOR (0.44) | MTORPIK3CANOS3NOS2ADK | |
| SCHEMBL1306099 | 0.79 | GRM5 (0.40) | — | |
| SCHEMBL10162703 | 0.79 | NOS3 (0.46) | MTORPIK3CANOS3NOS2ADK | |
| SCHEMBL503751 | 0.78 | CYP1A2 (0.55) | MTORPIK3CA | |
| SCHEMBL1914210 | 0.78 | GRM5 (0.39) | — | |
| SCHEMBL27847429 | 0.78 | GRM5 (0.39) | — | |
| SCHEMBL30583888 | 0.78 | CYP1A2 (0.55) | MTORPIK3CA | |
| SCHEMBL19775310 | 0.77 | MTOR (0.44) | MTORPIK3CANOS3NOS2ADK | |
| SCHEMBL1349094 | 0.77 | HSP90AA1 (0.35) | — | |
| SCHEMBL15448027 | 0.76 | GRM5 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390722-A | Organic small molecular compound capable of distinguishing and detecting hydrazine and hypochlorite and preparation method thereof | 华南理工大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118436643-A | Therapeutic strategy of ZAK inhibitor in targeted tumor and application thereof | 中国科学院上海营养与健康研究所 | 2024-08-06 | — | — | CN | disclosed |
| CN-118005630-A | ZAK inhibitor, preparation method and application thereof | 中国科学院上海营养与健康研究所 | 2024-05-10 | — | — | CN | disclosed |
| EP-4330253-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11667628-B2 | Compounds for imaging tau proteins that accumulate in brain | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667628-B2 | Compounds for imaging tau proteins that accumulate in brain | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2023-06-06 | — | — | US | disclosed |
| WO-2022232088-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| EP-1423368-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-06-02 | — | — | EP | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1373261-A2 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-6610714-B2 | HIV viricides | MEDIVIR AB (SE) | 2003-08-26 | — | — | US | disclosed |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-05-15 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
| WO-2003020705-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002070516-A2 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | MTOR 4367/4885PIK3CA 4552/4885NOS3 989/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | MTOR 4388/4885PIK3CA 3979/4885NOS3 1484/4885 |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD4, TEAD1, TEAD2 | MTOR 2038/4885PIK3CA 2007/4885NOS3 3715/4885 |
| US-11667628-B2 | Compounds for imaging tau proteins that accumulate in brain | MAPT, FABP7, HTT | MTOR 2739/4885PIK3CA 4064/4885NOS3 3318/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | MTOR 4388/4885PIK3CA 3979/4885NOS3 1484/4885 |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SUB1, HCFC1, CCR1 | MTOR 4406/4885PIK3CA 3191/4885NOS3 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.